Literature DB >> 284720

Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver.

P B Andreasen, L Hutters.   

Abstract

The pharmacokinetics of paracetamol were studied in 11 patients with cirrhosis of the liver and 12 controls. The average biological half-life after oral administration of 1 g paracetamol was significantly prolonged in patients with hepatic cirrhosis compared to the controls (3.7 hr vs.2.1 hr) and, correspondingly, the average plasma clearance was significantly reduced from 337 ml x min-1 in the controls to 162 ml x min-1 in the patients with cirrhosis of the liver. After subchronic dosing of paracetamol with 1 g paracetamol t. i. d. the plasma half-lives of paracetamol remained unchanged. Steady-state levels of paracetamol were significantly increased in the patients with cirrhosis of the liver. A significant correlation between the values of plasma clearance of paracetamol and prothrombin time (r = +0.88), galactose elimination capacity (r = +0.66), plasma albumin (r = +0.85) was found. No clinical or biochemical signs of hepatotoxicity were observed during the study.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 284720     DOI: 10.1111/j.0954-6820.1979.tb00728.x

Source DB:  PubMed          Journal:  Acta Med Scand Suppl        ISSN: 0365-463X


  16 in total

Review 1.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

Review 2.  Guide to drug dosage in hepatic disease.

Authors:  N M Bass; R L Williams
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

Review 3.  Can paracetamol (acetaminophen) be administered to patients with liver impairment?

Authors:  Kelly L Hayward; Elizabeth E Powell; Katharine M Irvine; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2015-12-25       Impact factor: 4.335

4.  Reduction of paracetamol and aspirin metabolism during viral hepatitis.

Authors:  C Jorup-Rönström; B Beermann; E Wåhlin-Boll; A Melander; S Britton
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

5.  The effect of acetaminophen administration on its disposition and body stores of sulphate.

Authors:  S Hendrix-Treacy; S M Wallace; K W Hindmarsh; G M Wyant; A Danilkewich
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

6.  Comparative pharmacokinetics and cardiovascular effects of tiapamil in healthy volunteers and patients with hepatic cirrhosis.

Authors:  P H Hinderling; M Eckert; S Gasic; H G Eichler; R Pötzi; P Heizmann
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 7.  Pharmacokinetics of common analgesics, anti-inflammatories and antipyretics in children.

Authors:  P D Walson; M E Mortensen
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

8.  Analgesics in patients with hepatic impairment: pharmacology and clinical implications.

Authors:  Marija Bosilkovska; Bernhard Walder; Marie Besson; Youssef Daali; Jules Desmeules
Journal:  Drugs       Date:  2012-08-20       Impact factor: 9.546

9.  Binding and disposition of sulfisoxazole in alcoholic cirrhosis.

Authors:  J P Cello; S Oie
Journal:  J Pharmacokinet Biopharm       Date:  1985-02

10.  Use of over-the-counter analgesics in patients with chronic liver disease: physicians' recommendations.

Authors:  Simona Rossi; David N Assis; Monica Awsare; Mark Brunner; Kevin Skole; Jitha Rai; Jocelyn Andrel; Steven K Herrine; Rajender K Reddy; Victor J Navarro
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.